Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. (21st February 2013)

• Record Type: Journal Article
• Authors: Abbas, Ola; Shamseddin, Ali; Temraz, Sally; Haydar, Ali
• Is Part Of: BMJ case reports. Volume 2013
• Publication Date: 2013-02-21
• Subjects: Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2012-007995
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterised by distinct radiological features. Common precipitants of this disorder include acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy and chemotherapy. We present the case of a patient with advanced ovarian carcinoma who developed PRES shortly after receiving bevacizumab (Avastin), an inhibitor of vascular endothelial growth factor. The patient's medical history and clinical presentation both suggest bevacizumab as the precipitator for PRES. This agent has been often overlooked as a possible cause of this rare neurological syndrome.